LaSalle St. Investment Advisors LLC Increases Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

LaSalle St. Investment Advisors LLC lifted its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 54.2% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 967 shares of the medical research company’s stock after purchasing an additional 340 shares during the quarter. LaSalle St. Investment Advisors LLC’s holdings in Thermo Fisher Scientific were worth $481,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Hirtle Callaghan & Co LLC purchased a new position in shares of Thermo Fisher Scientific in the 1st quarter valued at approximately $995,000. AlphaCore Capital LLC raised its position in shares of Thermo Fisher Scientific by 242.3% in the 1st quarter. AlphaCore Capital LLC now owns 5,566 shares of the medical research company’s stock valued at $2,772,000 after purchasing an additional 3,940 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. raised its position in shares of Thermo Fisher Scientific by 10.7% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 1,743,025 shares of the medical research company’s stock valued at $867,329,000 after purchasing an additional 167,971 shares during the last quarter. WealthPlan Investment Management LLC raised its position in Thermo Fisher Scientific by 52.6% during the 1st quarter. WealthPlan Investment Management LLC now owns 6,427 shares of the medical research company’s stock worth $3,198,000 after buying an additional 2,216 shares during the last quarter. Finally, Ironwood Investment Counsel LLC raised its position in Thermo Fisher Scientific by 6.0% during the 1st quarter. Ironwood Investment Counsel LLC now owns 581 shares of the medical research company’s stock worth $289,000 after buying an additional 33 shares during the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 8,000 shares of Thermo Fisher Scientific stock in a transaction on Thursday, August 7th. The shares were sold at an average price of $454.45, for a total transaction of $3,635,600.00. Following the sale, the chief executive officer owned 115,174 shares of the company’s stock, valued at $52,340,824.30. The trade was a 6.49% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction on Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the sale, the executive vice president directly owned 22,367 shares in the company, valued at approximately $10,735,712.66. This trade represents a 1.76% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 18,400 shares of company stock worth $8,345,792. 0.33% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Price Performance

Shares of NYSE TMO opened at $461.34 on Friday. The firm has a market cap of $174.21 billion, a PE ratio of 26.68, a PEG ratio of 2.43 and a beta of 0.74. The firm has a fifty day moving average of $426.80 and a 200 day moving average of $464.17. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping the consensus estimate of $5.22 by $0.14. The company had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The firm’s revenue was up 2.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $5.37 EPS. As a group, research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 0.4%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific’s payout ratio is 9.95%.

Analyst Upgrades and Downgrades

TMO has been the subject of a number of recent research reports. Raymond James Financial reissued an “outperform” rating and set a $535.00 price target (up from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. HSBC reissued a “hold” rating and set a $510.00 price target on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Stifel Nicolaus reduced their price target on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a “buy” rating for the company in a research report on Thursday, April 24th. Hsbc Global Res lowered shares of Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 24th. Finally, Wells Fargo & Company reduced their price target on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an “overweight” rating for the company in a research report on Thursday, July 24th. Six research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. According to data from MarketBeat.com, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and a consensus target price of $593.00.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.